TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

VIZAMYL

FLUTEMETAMOL F-18 Radiopharmaceutical Activity
Neurology Approved 2013-10-25
2
Indications
--
Phase 3 Trials
12
Years on Market

Details

Status
Prescription
First Approved
2013-10-25
Routes
INTRAVENOUS
Dosage Forms
INJECTABLE

Companies

Active Ingredient: FLUTEMETAMOL F-18

VIZAMYL Approval History

Loading approval history...

What VIZAMYL Treats

2 indications

VIZAMYL is approved for 2 conditions since its original approval in 2013. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Alzheimer's Disease
  • Cognitive Decline
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

VIZAMYL FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

VIZAMYL is indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheimer's disease (AD) and other causes of cognitive decline Selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products VIZAMYL is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for: Evaluation of Alzheim...

VIZAMYL Patents & Exclusivity

Latest Patent: Sep 2028

Patents (4 active)

US8916131 Expires Sep 16, 2028
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.